China Medical System Holdings (HKSE:00867) LT-Debt-to-Total-Asset : 0.00 (As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

What is China Medical System Holdings LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. China Medical System Holdings's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.00.

China Medical System Holdings's long-term debt to total assets ratio stayed the same from Dec. 2022 (0.00) to Dec. 2023 (0.00).

China Medical System Holdings LT-Debt-to-Total-Asset Historical Data

The historical data trend for China Medical System Holdings's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Medical System Holdings LT-Debt-to-Total-Asset Chart

China Medical System Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.05

0.04

China Medical System Holdings Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.04	-	-	-	-

China Medical System Holdings LT-Debt-to-Total-Asset Calculation

China Medical System Holdings's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	18.234	/	19393.615
	=	0.00

China Medical System Holdings's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )	/	Total Assets (Q: Dec. 2023 )
	=	18.234	/	19393.615
	=	0.00

China Medical System Holdings (HKSE:00867) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

China Medical System Holdings LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of China Medical System Holdings's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

China Medical System Holdings (HKSE:00867) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China Medical System Holdings Ltd (HKSE:00867) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

2M7C:Germany

Address

510 King’s Road, Unit 2106, 21st Floor, North Point, Island Place Tower, Hong Kong, HKG

Website

http://www.cms.net.cn

China Medical System Holdings Ltd is active in the healthcare segment. It is one of the leading China-based pharmaceutical services companies in the country. The company's business mainly involves the marketing, promotion, and sales of prescription pharmaceutical products manufactured by domestic pharmaceutical companies. Some of its products include Plendil; Salofalk; Combizym; Ganfule Capsules; Xidakang; Hirudoid; and others. Geographically, it derives revenue from China.

Executives

Treasure Sea Limited	2101 Beneficial owner
Lam Kong	2201 Interest of corporation controlled by you

China Medical System Holdings (HKSE:00867) Headlines

No Headlines